Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Hobbs FR. et al, (2024), Journal of Infection, 89
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Hayward G. et al, (2024), Journal of Infection, 88
Platform adaptive trial of novel antivirals for early treatment of COVID-19 in the community (PANORAMIC): Protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
Gbinigie O. et al, (2023), BMJ Open, 13
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Dorward J. et al, (2022), British Journal of General Practice, 72, E446 - E455
Emergency department management practices during the first year of COVID-19: A Rapid Review
Nixon MJ. et al, (2021), IMPLEMENTATION SCIENCE, 16
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Yu LM. et al, (2021), The Lancet, 398, 843 - 855
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Butler CC. et al, (2021), The Lancet Respiratory Medicine, 9, 1010 - 1020
Inclusion and diversity in the PRINCIPLE trial
Patel MG. et al, (2021), The Lancet, 397, 2251 - 2252
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Butler CC. et al, (2021), The Lancet, 397, 1063 - 1074
Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
PRINCIPLE Trial Collaborative Group None. et al, (2021)
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
PRINCIPLE Collaborative Group None. et al, (2021)
Determinants of Protective Behaviour Adoption and the Implications for Health Authorities During a Pandemic
Koshkouei M. and Nixon MJ., (2020), International journal of medicine and public health
The NASSS-CAT tools for understanding, guiding, monitoring, and researching technology implementation projects in health and social care: Protocol for an evaluation study in real-world settings
Greenhalgh T. et al, (2020), JMIR Research Protocols, 9
International Counterfeit Medicine Regulation
Koshkouei M., (2017), Fundamentals of International Regulatory Affairs
The Impact of the Falsified Medicines Directive in the Dispensing Operations of an Austrian Hospital Pharmacy
de CN P. et al, (2017), Journal of Hospital & Medical Management, 03